Immune-related Long Non-coding RNAs Can Serve As Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma

Overview

Journal Transl Androl Urol

Date 2021 Jul 23

PMID 34295734

Citations 5

Authors

Cheng Shan Li

Zhang Ze Lu

Da Lang Fang

Wei Jie Zhou

Jie Wei

Affiliations

Soon will be listed here.

Abstract

Background: The immune microenvironment is a critical regulator of clear cell renal cell carcinoma (ccRCC) progression. However, the underlying mechanisms the regulatory role of immune-related long non-coding RNAs (irlncRNAs) in the ccRCC tumor microenvironment (TME) are still obscure. Herein, we investigated prognostics role of irlncRNAs for ccRCC.

Methods: The raw data of patients with ccRCC were downloaded from The Cancer Genome Atlas (TCGA) database, and immune-related genes were obtained from the ImmPort database. First, we investigated the correlation between the immune-related genes and irlncRNAs. Then, we identified the differentially expressed irlncRNA pairs (ILRPs) between normal and cancer tissue samples, and prognostic model was constructed with the differentially expressed ILRPs. We further explored whether the signature risk scores of ILRPs had a considerable impact on immune cell infiltration. Finally, we performed a drug sensitivity analysis based on risk score.

Results: There were 13 upregulated and 40 downregulated irlncRNAs between the ccRCC and normal tissue samples. We further selected the irlncRNAs that significantly affect the prognosis of patients with ccRCC via univariate Cox, lasso regression, and multivariate regression analyses. Twelve ILRPs were used to construct a prognostic signature. The model showed the ILRPs model could be used to assess the prognosis of ccRCC patients. Study of the influence of risk score and clinical characteristics on the prognosis of patients with ccRCC showed risk score to be an independent factor affecting the outcome of ccRCC. We further performed the difference analysis of immune cell abundance between ccRCC and normal tissue samples. The results showed that patients with higher abundance of M0 macrophages, plasma cells, follicular helper T cells, and regulatory T cells (Tregs) had a poor outcome. Finally, we performed a drug sensitivity analysis based on risk score. The results showed that high-risk score patients are sensitive to orafenib, sunitinib, temsirolimus, cisplatin, and gemcitabine.

Conclusions: Our study has developed a novel and reasonable ILPRs model for prognostic prediction, which does not require transcriptional levels to be detected.

Citing Articles

Non-coding transcriptome profiles in clear-cell renal cell carcinoma.

Tesarova T, Fiala O, Hora M, Vaclavikova R Nat Rev Urol. 2024; 22(3):151-174.

PMID: 39242964 DOI: 10.1038/s41585-024-00926-3.

Fatty acid metabolism-related lncRNAs are potential biomarkers for survival prediction in clear cell renal cell carcinoma.

Zhang M, Yang B, Wang Z, Guo S Medicine (Baltimore). 2024; 103(8):e37207.

PMID: 38394500 PMC: 11309608. DOI: 10.1097/MD.0000000000037207.

LncRNA AGAP2 antisense RNA 1 stabilized by insulin-like growth factor 2 mRNA binding protein 3 promotes macrophage M2 polarization in clear cell renal cell carcinoma through regulation of the microRNA-9-5p/THBS2/PI3K-Akt pathway.

Xu P, Feng D, Wang J, Wang Y, Xie G, Zhang B Cancer Cell Int. 2023; 23(1):330.

PMID: 38110984 PMC: 10729468. DOI: 10.1186/s12935-023-03173-5.

Tang C, Qu G, Xu Y, Yang G, Wang J, Xiang M Aging (Albany NY). 2021; 13(24):26046-26062.

PMID: 34954690 PMC: 8751591. DOI: 10.18632/aging.203797.

Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.

Sun J, Xia Q, Liu C, Xu J, Xun Y, Lu J Dis Markers. 2021; 2021:8800358.

PMID: 34512816 PMC: 8429034. DOI: 10.1155/2021/8800358.

References

Buchatskii L, Litvinov G, Podrezova L . [Effect of physical and chemical factors on the iridovirus of the mosquito Aedes cantans]. Mikrobiol Zh (1978). 1986; 48(2):55-8. View

Liu Y, Li X, Zhang C, Zhang H, Huang Y . LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma. Cancer Sci. 2020; 111(10):3693-3704. PMC: 7541001. DOI: 10.1111/cas.14611. View

Jiang Y, Li W, Yan Y, Yao X, Gu W, Zhang H . LINC01094 triggers radio-resistance in clear cell renal cell carcinoma via miR-577/CHEK2/FOXM1 axis. Cancer Cell Int. 2020; 20:274. PMC: 7315499. DOI: 10.1186/s12935-020-01306-8. View

Hong W, Liang L, Gu Y, Qi Z, Qiu H, Yang X . Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma. Mol Ther Nucleic Acids. 2020; 22:937-947. PMC: 7670249. DOI: 10.1016/j.omtn.2020.10.002. View

Jiang Y, Gou X, Wei Z, Tan J, Yu H, Zhou X . Bioinformatics profiling integrating a three immune-related long non-coding RNA signature as a prognostic model for clear cell renal cell carcinoma. Cancer Cell Int. 2020; 20:166. PMC: 7222502. DOI: 10.1186/s12935-020-01242-7. View

Derakhshani A, Vahidian F, Alihasanzadeh M, Mokhtarzadeh A, Lotfi Nezhad P, Baradaran B . Mast cells: A double-edged sword in cancer. Immunol Lett. 2019; 209:28-35. DOI: 10.1016/j.imlet.2019.03.011. View

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356(22):2271-81. DOI: 10.1056/NEJMoa066838. View

Nassif E, Thibault C, Vano Y, Fournier L, Mauge L, Verkarre V . Sunitinib in kidney cancer: 10 years of experience and development. Expert Rev Anticancer Ther. 2016; 17(2):129-142. DOI: 10.1080/14737140.2017.1272415. View

Ye Z, Duan J, Wang L, Ji Y, Qiao B . LncRNA-LET inhibits cell growth of clear cell renal cell carcinoma by regulating miR-373-3p. Cancer Cell Int. 2019; 19:311. PMC: 6873579. DOI: 10.1186/s12935-019-1008-6. View

10.

Gajewski T, Schreiber H, Fu Y . Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14(10):1014-22. PMC: 4118725. DOI: 10.1038/ni.2703. View

11.

Lam J, Belldegrun A, Pantuck A . Long-term outcomes of the surgical management of renal cell carcinoma. World J Urol. 2006; 24(3):255-66. DOI: 10.1007/s00345-006-0055-5. View

12.

Huang J, Chen M, Chen D, Gao X, Zhu S, Huang H . A Peptide Encoded by a Putative lncRNA HOXB-AS3 Suppresses Colon Cancer Growth. Mol Cell. 2017; 68(1):171-184.e6. DOI: 10.1016/j.molcel.2017.09.015. View

13.

Jiang W, Kai J, Li D, Wei Z, Wang Y, Wang W . lncRNA HOXB-AS3 exacerbates proliferation, migration, and invasion of lung cancer via activating the PI3K-AKT pathway. J Cell Physiol. 2020; 235(10):7194-7203. DOI: 10.1002/jcp.29618. View

14.

Qu L, Wang Z, Chen Q, Li Y, He H, Hsieh J . Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Eur Urol. 2018; 74(6):756-763. DOI: 10.1016/j.eururo.2018.07.032. View

15.

Zhou B, Guo W, Sun C, Zhang B, Zheng F . Linc00462 promotes pancreatic cancer invasiveness through the miR-665/TGFBR1-TGFBR2/SMAD2/3 pathway. Cell Death Dis. 2018; 9(6):706. PMC: 5999603. DOI: 10.1038/s41419-018-0724-5. View

16.

Papadopoulos E, Yousef G, Scorilas A . Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes. Tumour Biol. 2015; 36(5):3197-207. DOI: 10.1007/s13277-014-2190-8. View

17.

Cohen H, McGovern F . Renal-cell carcinoma. N Engl J Med. 2005; 353(23):2477-90. DOI: 10.1056/NEJMra043172. View

18.

Fu Z, Jiao Y, Li Y, Ji B, Jia B, Liu B . TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer. Medicine (Baltimore). 2019; 98(51):e18487. PMC: 6940182. DOI: 10.1097/MD.0000000000018487. View

19.

Sammarco G, Varricchi G, Ferraro V, Ammendola M, De Fazio M, Altomare D . Mast Cells, Angiogenesis and Lymphangiogenesis in Human Gastric Cancer. Int J Mol Sci. 2019; 20(9). PMC: 6540185. DOI: 10.3390/ijms20092106. View

20.

DAvella C, Abbosh P, Pal S, Geynisman D . Mutations in renal cell carcinoma. Urol Oncol. 2018; 38(10):763-773. DOI: 10.1016/j.urolonc.2018.10.027. View